Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of RY_SW01 Cell Injection Therapy in Systemic Sclerosis

NCT06058091 is registered in ClinicalTrials.gov with Jiangsu Renocell Biotech Company as lead sponsor.

NCT NCT06058091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06058091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of RY_SW01 Cell Injection Therapy in Systemic Sclerosis
Lead sponsor
Jiangsu Renocell Biotech Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 22, 2023
Completion date
December 31, 2035
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis